Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1133452

Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer

Terlević, Robert; Perić Balja, Melita; Tomas, Davor; Skenderi, Faruk; Krušlin, Božo; Vranić, Semir; Demirović, Alma
Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer // Annals of diagnostic pathology, 38 (2019), 62-66 doi:10.1016/j.anndiagpath.2018.11.002 (međunarodna recenzija, članak, ostalo)

CROSBI ID: 1133452 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer

Autori
Terlević, Robert ; Perić Balja, Melita ; Tomas, Davor ; Skenderi, Faruk ; Krušlin, Božo ; Vranić, Semir ; Demirović, Alma

Izvornik
Annals of diagnostic pathology (1092-9134) 38 (2019); 62-66

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
immunohistochemistry ; neuroendocrine breast cancer ; somatostatin receptors

Sažetak
Neuroendocrine breast cancer (NEBC) is a group of rare tumors, which could benefit from therapy targeting the somatostatin receptors (SSTRs). In particular, SSTR2A and SSTR5 are potential targets given their consistent expression in gastrointestinal and pancreatic primary and metastatic neuroendocrine cancers. Currently, there are no studies describing the expression of SSTRs in NEBC. The purpose of our study was to characterize the immunohistochemical expression of SSTR2A and SSTR5 in a cohort of NEBC. Thirty- one primary NEBC cases were analyzed, and SSTR2A and SSTR5 immunohistochemistry performed and scored using the modified immunoreactive score proposed by Remmele and Stanger. All patients were females with a mean age of 66.6 years (SD = 14). 77% of cases were histological grade 2. SSTR2A showed a weak positivity in 11 cases (35.5%), moderate positivity in 6 cases (19.4%) and strong positivity in 5 cases (16.1%). Nine cases were negative for SSTR2A (29%). SSTR5 showed a weak positivity in 16 cases (51.6%), moderate positivity in 6 cases (19.4%), while no cases showed strong positivity. Nine cases were negative for SSTR5 (29%). Five cases were negative for both SSTR2A and SSTR5. A weak to moderate SSTR2A and SSTR5 expression was observed in 50-70% of the cases. A subset of NEBCs with strong SSR2A expression may benefit from SSTRs targeted therapy. These results need further validation in a larger series including metastatic NEBC, to provide potential therapeutic targets for patients with advanced disease.

Izvorni jezik
Engleski

Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA

Ustanove:
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Opća bolnica Pula

Profili:

Avatar Url Faruk Skenderi (autor)

Avatar Url Alma Demirović (autor)

Avatar Url Melita Perić Balja (autor)

Avatar Url Robert Terlević (autor)

Avatar Url Davor Tomas (autor)

Avatar Url Božo Krušlin (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com

Citiraj ovu publikaciju:

Terlević, Robert; Perić Balja, Melita; Tomas, Davor; Skenderi, Faruk; Krušlin, Božo; Vranić, Semir; Demirović, Alma
Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer // Annals of diagnostic pathology, 38 (2019), 62-66 doi:10.1016/j.anndiagpath.2018.11.002 (međunarodna recenzija, članak, ostalo)
Terlević, R., Perić Balja, M., Tomas, D., Skenderi, F., Krušlin, B., Vranić, S. & Demirović, A. (2019) Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Annals of diagnostic pathology, 38, 62-66 doi:10.1016/j.anndiagpath.2018.11.002.
@article{article, author = {Terlevi\'{c}, Robert and Peri\'{c} Balja, Melita and Tomas, Davor and Skenderi, Faruk and Kru\v{s}lin, Bo\v{z}o and Vrani\'{c}, Semir and Demirovi\'{c}, Alma}, year = {2019}, pages = {62-66}, DOI = {10.1016/j.anndiagpath.2018.11.002}, keywords = {immunohistochemistry, neuroendocrine breast cancer, somatostatin receptors}, journal = {Annals of diagnostic pathology}, doi = {10.1016/j.anndiagpath.2018.11.002}, volume = {38}, issn = {1092-9134}, title = {Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer}, keyword = {immunohistochemistry, neuroendocrine breast cancer, somatostatin receptors} }
@article{article, author = {Terlevi\'{c}, Robert and Peri\'{c} Balja, Melita and Tomas, Davor and Skenderi, Faruk and Kru\v{s}lin, Bo\v{z}o and Vrani\'{c}, Semir and Demirovi\'{c}, Alma}, year = {2019}, pages = {62-66}, DOI = {10.1016/j.anndiagpath.2018.11.002}, keywords = {immunohistochemistry, neuroendocrine breast cancer, somatostatin receptors}, journal = {Annals of diagnostic pathology}, doi = {10.1016/j.anndiagpath.2018.11.002}, volume = {38}, issn = {1092-9134}, title = {Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer}, keyword = {immunohistochemistry, neuroendocrine breast cancer, somatostatin receptors} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.